Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory…
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory…
Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated…
Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated…
LONDON and DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) — Spectral MD Holdings, Ltd. (AIM: SMD), an artificial…
LONDON and DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) — Spectral MD Holdings, Ltd. (AIM: SMD), an artificial…
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia B…
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia B…
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V….
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V….
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent….
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent….
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A…
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A…
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023…
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023…
Financing led by RA Capital Management with participation from new and existing investors Expected net…
Financing led by RA Capital Management with participation from new and existing investors Expected net…
For the three months ended June 30, 2023: Revenues of $793.0 million GAAP net income…
For the three months ended June 30, 2023: Revenues of $793.0 million GAAP net income…
VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and…